Melanoma/Skin Cancer News

The Parker Institute for Cancer Immunotherapy awarded nearly $3 million worth of grants to six early career researchers.

Ute Dugan, MD, PhD, has been appointed senior vice president for clinical research at Parker Institute for Cancer Immunotherapy.

Patients previously treated with hedgehog inhibitors for locally advanced basal cell carcinoma saw “clinical benefit” when treated with cemiplimab, according to a presentation at South Beach Symposium Medical Dermatology Summit.

A number of epidermal growth factor receptor inhibitors used in the oncology setting continue to demonstrate impacts on keratinocyte growth and cause adverse skin reactions, according to a study.

Mortality associated with Merkle cell carcinoma may be lower among women compared with men, according to a retrospective study.

Pathological response should be an early surrogate endpoint for clinical trials of neoadjuvant therapy for melanoma, according to results of a pooled analysis published in Nature Medicine.

Sonidegib efficacy in patients with locally advanced basal cell carcinoma was not affected by concomitant cardiovascular medications, according to a presentation at Maui Derm for Dermatologists.

Patients’ response to anti-CTLA-4 or anti-PD-1 checkpoint therapy for advanced melanoma, and their incidence of immune-related adverse events of grade 3 or higher, were similar regardless of preexisting autoimmune disease, according to data.

Patients with a stage III melanoma mutation treated with dabrafenib plus trametinib had longer restricted mean survival times compared with placebo, according to an analysis of a phase 3 trial presented at Maui Derm for Dermatologists.

Circulating tumor DNA measurements before and during treatment could help guide selection of therapy for patients with BRAF V600-mutant unresectable or metastatic melanoma, according to study results published in The Lancet Oncology.